| scholarly article | Q13442814 |
| P50 | author | Ritva Heljasvaara | Q54531504 |
| Mariano Esteban | Q30004051 | ||
| P2093 | author name string | Vicente Larraga | |
| Pilar Lucas | |||
| Gustavo del Real | |||
| Dolores Rodriguez | |||
| Juan R Rodriguez | |||
| Rosa M Gonzalo | |||
| P2860 | cites work | Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis | Q37574082 |
| Genetic vaccination against leishmaniasis | Q45026373 | ||
| Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants | Q45750927 | ||
| Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells | Q73948770 | ||
| Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine | Q24650662 | ||
| Molecular cloning, cell localization and binding affinity to DNA replication proteins of the p36/LACK protective antigen from Leishmania infantum | Q30657332 | ||
| DNA vaccines. | Q31994282 | ||
| Expression of the firefly luciferase gene in vaccinia virus: a highly sensitive gene marker to follow virus dissemination in tissues of infected animals | Q33558384 | ||
| Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection | Q33604990 | ||
| Induction of CD8+ T cells using heterologous prime-boost immunisation strategies | Q33776098 | ||
| Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. | Q34001298 | ||
| A striking property of recombinant poxviruses: efficient inducers of in vivo expansion of primed CD8(+) T cells | Q34132562 | ||
| Applications of pox virus vectors to vaccination: an update | Q34403246 | ||
| Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice | Q35118989 | ||
| Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis | Q35437937 | ||
| Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice | Q36014035 | ||
| Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria | Q36343961 | ||
| Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major | Q36380692 | ||
| Expression cloning of a protective Leishmania antigen | Q36701227 | ||
| Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques | Q36952733 | ||
| P433 | issue | 7-8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Leishmania infantum | Q1950789 |
| Vaccinia virus | Q1986297 | ||
| P304 | page(s) | 1226-1231 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis | |
| P478 | volume | 20 |
| Q47805253 | A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major |
| Q40415127 | A heterologous prime/boost immunisation strategy protects against virulent E. ruminantium Welgevonden needle challenge but not against tick challenge. |
| Q97529723 | A second generation leishmanization vaccine with a markerless attenuated Leishmania major strain using CRISPR gene editing |
| Q43703628 | Analysis of the 96 most often cited articles published in veterinary journals in 2002 and 2003. |
| Q61690576 | Antibiotic resistance free plasmid DNA expressing LACK protein leads towards a protective Th1 response against Leishmania infantum infection |
| Q36684637 | Baculovirus vectors elicit antigen-specific immune responses in mice |
| Q50643413 | Boosting systemic and secreted antibody responses in mice orally immunized with recombinant Bacillus subtilis strains following parenteral priming with a DNA vaccine encoding the enterotoxigenic Escherichia coli (ETEC) CFA/I fimbriae B subunit. |
| Q28539852 | Clinical and parasitological protection in a Leishmania infantum-macaque model vaccinated with adenovirus and the recombinant A2 antigen |
| Q41768625 | Cloning and Expression of Recombinant Plasmid Containing P36/LACK Gene of Leishmania infantum Iranian Strain. |
| Q35802037 | Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability |
| Q37290119 | Cutaneous leishmaniasis: progress towards a vaccine |
| Q36915067 | DNA Vaccines against Protozoan Parasites: Advances and Challenges |
| Q46791764 | DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB/c mice |
| Q35023899 | DNA prime and peptide boost immunization protocol encoding the Toxoplasma gondii GRA4 induces strong protective immunity in BALB/c mice |
| Q55036231 | DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice. |
| Q33208276 | DNA vaccines and their application against parasites--promise, limitations and potential solutions. |
| Q35164804 | DNA vaccines for non-infectious diseases: new treatments for tumour and allergy |
| Q24801950 | DNA vaccines: designing strategies against parasitic infections |
| Q36445502 | DNA-Salmonella enterica serovar Typhimurium primer-booster vaccination biases towards T helper 1 responses and enhances protection against Leishmania major infection in mice |
| Q35207606 | Development of Vaccines against Visceral Leishmaniasis |
| Q35192190 | Development of a leishmaniasis vaccine: the importance of MPL. |
| Q80823805 | Dramatic improvement in FMD DNA vaccine efficacy and cross-serotype antibody induction in pigs following a protein boost |
| Q41404819 | Head-to-head comparison of three vaccination strategies based on DNA and raw insect-derived recombinant proteins against Leishmania. |
| Q42957095 | Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis |
| Q35689200 | Heterologous priming-boosting with DNA and modified vaccinia virus Ankara expressing tryparedoxin peroxidase promotes long-term memory against Leishmania major in susceptible BALB/c Mice |
| Q39450472 | Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leis |
| Q33693899 | Identifying vaccine targets for anti-leishmanial vaccine development |
| Q46832650 | Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis |
| Q35845737 | Induction of protective CD4+ T cell-mediated immunity by a Leishmania peptide delivered in recombinant influenza viruses |
| Q36251325 | Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania |
| Q36726750 | Leishmania vaccines: progress and problems. |
| Q47556262 | Leishmaniasis in humans: drug or vaccine therapy? |
| Q34033343 | Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis |
| Q40822231 | NYVAC vector modified by C7L viral gene insertion improves T cell immune responses and effectiveness against leishmaniasis |
| Q39313487 | Not All Antigens Are Created Equally: Progress, Challenges, and Lessons Associated with Developing a Vaccine for Leishmaniasis. |
| Q52009810 | Optimization of DNA vaccination against cutaneous leishmaniasis. |
| Q33818084 | Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice |
| Q73389208 | Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK |
| Q35873792 | Recent advances in vaccines for leishmaniasis |
| Q58647150 | Searching Genes Encoding Leishmania Antigens for Diagnosis and Protection |
| Q45728663 | The combination of DNA vectors expressing IL-12 + IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36 |
| Q35972642 | Towards development of novel immunization strategies against leishmaniasis using PLGA nanoparticles loaded with kinetoplastid membrane protein-11 |
| Q34533591 | Vaccination with L. infantum chagasi nucleosomal histones confers protection against new world cutaneous leishmaniasis caused by Leishmania braziliensis |
| Q34754538 | Vaccines for leishmaniasis in the fore coming 25 years. |
Search more.